DOCSLIB.ORG

Potassium Channel Blocker Activates Extracellular Signal-Regulated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potassium Channel Blocker Activates Extracellular Signal-Regulated View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 38, No. 5, 2001 © 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01558-3 Potassium Channel Blocker Activates Extracellular Signal-Regulated Kinases Through Pyk2 and Epidermal Growth Factor Receptor in Rat Cardiomyocytes Satoko Tahara, MD,* Keiichi Fukuda, MD, PHD,† Hiroaki Kodama, MD,* Takahiro Kato, MD,* Shunichiro Miyoshi, MD, PHD,‡ Satoshi Ogawa, MD, PHD* Tokyo, Japan ϩ OBJECTIVES We sought to determine whether potassium (K ) channel blockers (KBs) can activate extracellular signal-regulated kinase (ERK) and to characterize the upstream signals leading to ERK activation in cardiomyocytes. ϩ BACKGROUND Because KBs attenuate K outward current, they may possibly prolong the duration of action ϩ ϩ potentials, leading to an increase in calcium (Ca2 ) transient ([Ca2 ] ) in cardiomyocytes. ϩ i ϩ Elevation of intracellular Ca2 levels can trigger various signaling events. Influx of Ca2 ϩ through L-type Ca2 channels after membrane depolarization induced activation of MEK and ERK through activation of Ras in neurons. Although KBs are frequently used to treat cardiac arrhythmias, their effect on signaling pathways remains unknown. METHODS Primary cultured rat cardiomyocytes were stimulated with four different KBs—4- aminopyridine (4-AP), E-4031, tetra-ethylammonium and quinidine—and phosphorylation of ERK, proline-rich tyrosine kinase 2 (Pyk2) and epidermal growth factor receptor (EGFR) was detected. Action potentials were recorded by use of a conventional microelectrode. 2ϩ (Ca )i was monitored by the fluorescent calcium indicator Fluo-4. RESULTS E-4031, 4-AP, tetra-ethylammonium and quinidine induced phosphorylation of ERK. 2ϩ 4-Aminopyridine prolonged the duration of action potentials by 37% and increased (Ca )i by 52% at 1 mmol/l. Pre-incubation of ethyleneglycoltetraacetic acid, 1,2-bis(2- aminophenoxy)-ethane-N,N,NЈ,NЈ-tetraacetic acid tetrakis and diltiazem completely blocked this phosphorylation, whereas flufenamic acid and benzamil did not. 4-Aminopyridine induced tyrosine phosphorylation of Pyk2 and EGFR, which peaked at 5 and 10 min, respectively. Cytochalasin D, AG1478 and dominant-negative EGFR strongly inhibited the phosphorylation of ERK, whereas calphostin C, calmidazolium and KN62 did not. ϩ CONCLUSIONS These findings indicate that KBs induce ERK activation, which starts with Ca2 entry ϩ through the L-type Ca2 channel in cardiomyocytes, and that EGFR and Pyk2 are involved in this activation. (J Am Coll Cardiol 2001;38:1554–63) © 2001 by the American College of Cardiology Since the Cardiac Arrhythmia Suppression Trial was re- sarcoplasmic reticulum (1,2). Potassium channel blockers, ϩ ϩ ported, sodium (Na ) channel blockers have been consid- such as 4-aminopyridine (4-AP), which block K outward ered to deteriorate the prognosis of patients with cardiac currents and prolong the action potential duration (APD), ϩ 2ϩ 2ϩ arrhythmias. Sodium channel blockers decrease Na entry, increase Ca transient ([Ca ]i) in cardiomyocytes (3,4). ϩ which, in turn, decreases calcium (Ca2 ) influx through These data indicate that KBs could exert potentiating effects ϩ ϩ L-type Ca2 channels. Consequently, the decreased Ca2 on contractility by increasing the amplitude of intracellular 2ϩ influx has a negative inotropic effect on cardiomyocytes. In [Ca ]i. ϩ contrast, potassium (K ) channel blockers (KBs) were Mitogen-activated protein kinase (MAPK) family pro- expected to be used more frequently than before. Recent teins transduce signal from diverse receptor types, including ϩ studies have demonstrated that KBs inhibit K outward receptor protein tyrosine kinases, G-protein-coupled recep- current, which, in turn, causes prolongation of action tors and cytokine receptors, and play an important role in potentials. Prolongation of action potentials results in a the proliferation and differentiation of various cell types ϩ ϩ substantial increase in net Ca2 entry through L-type Ca2 (5,6). Among this family, extracellular signal-regulated ϩ channels, and this augmented Ca2 influx enhances myo- kinase (ERK) has been reported to be activated by various ϩ cardial contractility by increasing Ca2 release from the cytokines and growth factors, such as phenylephrine, endothelin-1, angiotensin II and leukemia inhibitory factor From the *Cardiopulmonary Division, Department of Internal Medicine; †Insti- (7), as well as by mechanical stretching in cardiomyocytes. tute for Advanced Cardiac Therapeutics; and the ‡Department of Physiology, Keio University School of Medicine, Tokyo, Japan. This study was supported by research The activation of ERK requires phosphorylation of both a grants from the Ministry of Education, Science and Culture, Japan, and Health threonine and a tyrosine residue by a dual-specificity kinase Science Research Grants for Advanced Medical Technology from the Ministry of known as MEK (MAPK/ERK kinase). Activated ERK Welfare, Japan. Manuscript received November 29, 2000; revised manuscript received June 27, translocates into the nucleus and can phosphorylate a variety 2001, accepted July 19, 2001. of nuclear transcription factors, suggesting that ERK is a JACC Vol. 38, No. 5, 2001 Tahara et al. 1555 November 1, 2001:1554–63 KB-Evoked Signals in Cardiomyocytes current resistance of 15 to 30 M⍀, were selected. Mem- Abbreviations and Acronyms brane potentials were measured in the current clamp mode 4-AP ϭ 4-aminopyridine (MEZ-8300, Nihon Kohden, Tokyo, Japan) and stored on APD ϭ action potential duration digital magnetic tape (frequency range 0 to 20 kHz; Sony ϭ BAPTA-AM 1,2-bis(2-aminophenoxy)-ethane- Magnescale, Sony Co., Tokyo, Japan) for later analysis. N,N,NЈ,NЈ-tetraacetic acid tetrakis ϩ Ca2 ϭ calcium During measurements, the cells were field-stimulated by 2ϩ ϭ 2ϩ [Ca ]i Ca transient 7-ms pulses at 1 Hz with a step-pulse generator (SET- EGFR ϭ epidermal growth factor receptor 1201, Nihon Kohden, Tokyo, Japan). ϭ ؉ ϩ ERK extracellular signal-regulated kinase Measurement of [Ca2 ] . The [Ca2 ] transient was mon- HA ϭ hemaggulutinin i i ϩ K ϭ potassium itored by use of the fluorescent calcium indicator Fluo-4 KB ϭ potassium channel blocker (Molecular Probes, Eugene, Oregon), as described previ- LIF ϭ leukemia inhibitory factor ously (12). During measurements, the cells were field- MAPK ϭ mitogen-activated protein kinase stimulated by 7-ms pulses at 1 Hz. MEK ϭ MAPK/ERK kinase ϩ Reagents and antibodies. Potassium channel blockers, Na ϭ sodium PKC ϭ protein kinase C including 4-AP, 1-(2-[6-methyl-2-pyridil]-ethyl)-4-(4- Pyk2 ϭ proline-rich tyrosine 2 methylsulfonylaminobenzoyl)-piperidine (E-4031, Eisai, TEA ϭ tetra-ethylammonium Tokyo, Japan), tetra-ethylammonium (TEA) and quini- dine, were purchased from Sigma Chemical Co., Ltd. (Tokyo, Japan). Anti-phospho-ERK antibody was pur- key mediator of transduction of cytoplasmic signals to chased from New England Biolabs (Boston, Massachu- nuclear responses. setts). Anti-phosphotyrosine antibody (RC20H) was pur- ϩ Elevation of intracellular Ca2 levels can trigger various chased from Transduction Laboratories (Lexington, ϩ signaling events. Rosen et al. (8) reported that Ca2 influx Kentucky). Anti-Pyk2 and anti-EGFR antibodies were ϩ through L-type voltage-dependent Ca2 channels after purchased from Santa Cruz Biotechnology, Inc. (Santa membrane depolarization induced activation of MEK and Cruz, California). MAPK through activation of Ras in neurons. Moreover, Immunoprecipitation and Western blot analysis. The 2ϩ Ca influx after membrane depolarization was recently cells were lysed with a buffer, as described previously (7). reported to mediate ligand-independent transactivation of Lysates were incubated with either anti-EGFR or anti- epidermal growth factor receptor (EGFR) in PC12 cells Pyk2 antibody at 4°C for 4 h, followed by protein A- or (9,10). Subsequently, we directed our attention to KBs and G-sepharose (Sigma) for 2 h, and immunoprecipitated. investigated whether the use of KBs can activate the ERK Proteins were separated by 6% sodium dodecyl sulfate- 2ϩ pathway through Ca -dependent signaling. Moreover, we polyacrylamide gel electrophoresis (SDS-PAGE) and im- also explored the upstream signals leading to ERK activa- munoblotted with anti-phosphotyrosine antibody. Western tion by KBs. Here, we report that KBs can induce ERK ϩ blot analysis for phospho-ERK was performed, as described activation, which is initiated by Ca2 entry through L-type 2ϩ previously (7). The signals were visualized by enhanced Ca channels, and that EGFR and proline-rich tyrosine 2 chemiluminescence (Amersham Pharmacia Biotech, Buck- (Pyk2) are critically involved in KB-induced ERK activation inghamshire, England). in cardiomyocytes. Transfection of plasmids and in vitro kinase assay. Tranasfection of plasmids was performed using effectene METHODS transfection reagent (Qiagen, Hilden, Germany), according Cell culture. Primary cultures of cardiomyocytes were to the manufacturer’ s instructions. The deletion mutant prepared from the ventricles of one-day-old neonatal Wistar (533del) of human EGFR (EGFRdel) was provided by rats, as described previously (11). At 48 h after seeding, the Murasawa et al. (13). Hemaggulutinin-tagged ERK2 plas- culture medium was changed to medium containing 0.5% mid (HA-ERK2) with the SV40 promoter was provided by fetal bovine serum, incubated for 6 h,
Load more

Recommended publications
  • Rodgers 693..696
    Copyright #ERS Journals Ltd 1999 Eur Respir J 1999; 14: 693±696 European Respiratory Journal Printed in UK ± all rights reserved ISSN 0903-1936 The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis H.C. Rodgers, A.J. Knox The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Respiratory Medicine Unit, City Hospital, H.C. Rodgers, A.J. Knox. #ERS Journals Ltd 1999. Hucknall Road, Nottingham, NG5 IPB. ABSTRACT: The electrochemical defect in the bronchial epithelium in cystic fibrosis (CF) consists of defective chloride secretion and excessive sodium reabsorption. The Correspondence: A.J. Knox Respiratory Medicine Unit sodium channel blocker, amiloride, has been shown to reversibly correct the sodium Clinical Sciences Building reabsorption in CF subjects, but long term studies of amiloride have been disap- City Hospital pointing due to its short duration of action. Benzamil, a benzyl substituted amiloride Hucknall Road analogue, has a longer duration of action than amiloride in cultured human nasal Nottingham NG5 lPB epithelium. The results of the first randomized, placebo controlled, double blind, UK crossover study are reported here comparing the effects of benzamil and amiloride on Fax: 0115 9602140 nasal potential difference (nasal PD) in CF. Ten adults with CF attended on three occasions. At each visit baseline nasal PD was Keywords: Amiloride -3 -3 benzamil recorded, the drug (amiloride 1610 M, benzamil 1.7610 M, or 0.9% sodium cystic fibrosis chloride) was administered topically via a nasal spray, and nasal PD was measured at nasal potential difference 15, 30 min, 1, 2, 4 and 8 h.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Documentation for All Data Sets
    Documentation for all Data Sets HEALTH ABC DATA ANALYSIS FILE....................................................................................... 2 PARTICIPANT HISTORY FILE (PH)............................................................................................. 2 YEAR 10 VISIT DATA (Y10Visit).................................................................................................. 5 YEAR 10 PROXY CONTACT DATA (Y10Proxy)......................................................................... 7 114-month SEMI-ANNUAL TELEPHONE CONTACT DATA (SA114Mo)................................. 9 114-month PROXY CONTACT DATA (SA114Prox)................................................................... 10 MISSED FOLLOW-UP CONTACT DATA (MissVis).................................................................. 11 SPECIAL MISSING VALUE CODES........................................................................................... 13 DROPPED VARIABLES................................................................................................................ 15 LISTINGS ................................................................................................................................ 15 DATA DICTIONARY .................................................................................................................... 16 Appendix I DROPPED VARIABLES AND ALTERNATES ............................................................. 17 Appendix II 114-MONTH CALCULATED VARIABLES................................................................
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Investigating Neuroprotectants for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
    THE UNIVERSITY OF NEW SOUTH WALES Translational Neuroscience Facility School of Medical Sciences Faculty of Medicine UNSW Australia A thesis in fulfilment of the requirements for the degree of: Masters Investigating Neuroprotectants for the Treatment of Chemotherapy-Induced Peripheral Neuropathy by Munawwar Abdulla Supervisor: Dr. Gila Moalem-Taylor Co-supervisor: Dr. Justin Lees Co-supervisor: Dr. Patsie Pollie August, 2018 i The University of New South Wales Thesis/Dissertation Sheet Surname or Family name: Abdulla First name/s: Munawwar Abbreviation for degree as given in the University calendar: MSc School: School of Medical Sciences Faculty: Medicine Title: Investigating neuroprotectants for the treatment of chemotherapy-induced peripheral neuropathy Abstract 350 words maximum: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting side effect of many chemotherapy regimens and is becoming a more prevalent issue as the longevity of cancer patients continues to increase. Sensory symptoms include neuropathic pain, paraesthesia, and numbness and usually spread in a glove-and-stocking distribution. At present, there are no effective medications to treat or prevent CIPN, and the mechanisms by which symptoms are induced have not been fully elucidated. Paclitaxel (PTX) is a commonly used chemotherapeutic that induces neuropathy in a high percentage of patients. The broad aim of this thesis was to establish a model of CIPN in vitro and in vivo and test clinically approved drugs for potential neuroprotective effects. Since the dorsal root ganglion (DRG) has been implicated in CIPN, we cultured dissociated primary DRG neurons from 5-week-old C57BL/6 mice and treated them with PTX to observe neurotoxic effects.
    [Show full text]
  • Characterization of Na+ Transport Across the Cell Membranes of the Was Actively Reabsorbed in This Segment [61
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney Internationa4 VoL 47 (1995), pp. 789—794 Characterization of Na transport across the cell membranes of the ascending thin limb of Henle's loop NOBUYUKI TMcAIsHI, YOSHIAKI KONDO, IKUMA FuJIwA1tzi, OSAMU ITO, YUTAKA IGARASHI, and KEISHI ABE Department of Clinical Biology and Hormonal Regulation, Department of Pediatrics, and The Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan Characterization of Na+ transport across the cell membranes of the was actively reabsorbed in this segment [61. Later in vivo studies ascending thin limb of Henle's loop. In the ascending thin limb of Henle's using electrodes with increased reliability found a lumen-positive loop (ATL), intracellular Nat is extruded by Nat/KtATPase in the basolateral membrane. To further characterize Nat transport across the Vt under free-flow conditions in the ATE [3—71, but did not cell membranes of the ATL, the intracellular sodium concentrationresolve the issue of whether active Cl reabsorption was respon- ([Nat];) was monitored using a sodium-sensitive fluorescent probe, SBFI, sible for lumen-positive potentials. In vitro studies demonstrated in the in vitro microperfused hamster ATE Basal [Nat]1 was 19.0 1.2 the absence of active NaCl reabsorption in the Alt and found no mM (N =24).Removal and replacement of luminal Nat did not change [Nat]1 in the presence of Nat in the bathing fluid. In contrast, luminal evidence for a spontaneous Vt or net reabsorption of NaCl Nat removal reduced [Nat]1 from 11.6 0.9 to 6.3 0.8 m in the[8—101.
    [Show full text]
  • SUPPLEMENTAL INFORMATION Potassium Acts Through
    SUPPLEMENTAL INFORMATION Potassium acts through mTOR to regulate its own secretion Brief title: K+ regulates mTOR Mads Vaarby Sørensen1,2,*, Bidisha Saha3,*, Iben Skov Jensen1, Peng Wu4, Niklas Ayasse1, Catherine E. Gleason3, Samuel Levi Svendsen1, Wen-Hui Wang4, and David Pearce3 1Department of Biomedicine. Physiology, Health, Aarhus University, Ole Worms Allé 3, 8000 Aarhus C, Denmark. 2Aarhus Institute for Advanced Studies (AIAS), Aarhus University. Hoegh-Guldbergs Gade 6B, 8000 Aarhus C, Denmark. 3University of California at San Francisco, San Francisco, CA, USA, Department of Medicine, Division of Nephrology, Department of Cellular and Molecular Pharmacology. 4Department of Pharmacology, New York Medical College, Valhalla, New York 10595 *These two authors contributed equally to this work 1 Supplemental Methods Materials Dulbecco’s modified Eagle medium (DMEM) with high glucose (4.5g/Liter) (CCFAA005) and K+ free DMEM with high glucose (4.5g/Liter) (CCFDA003) and penicillin-streptomycin were purchased from the UCSF Cell Culture Facility. Fetal bovine serum (FBS) was from Atlanta Biologicals; L-Glutamine, Trypsin and Collagen I were from Corning. Polyethyleneimine “MAX” (MW 40,000) transfection reagent was from Polysciences, Inc (Cat # 24756). GSK650394 were from Tocris; AZD8055 was from SelleckChem; rapamycin,amiloride benzamil were from Sigma- Aldrich. PP242 was kind gift from Kevan Shokat, UCSF. VU0134992 was provided by Dr. Sujay Kharade and Prof. Jerod S. Denton (Vanderbilt University Medical Center). Bradford Assay Reagent was purchased from ThermoFisher (Cat# 1856209). ECL Western Blotting Detection reagent was obtained from GE Heathcare. Benzamil injections Benzamil is a specific ENaC antagonist (1). 0.2 μg/g BW benzamil (0.4mg/ml dissolved in 0.9 % saline with 0.5 % DMSO) (Sigma-Aldrich) or vehicle (5 % DMSO in 0.9 % saline) was administrated via intraperitoneal (i.p.) injections 15 minutes prior to gavage.
    [Show full text]
  • Sodium Channel Na Channels;Na+ Channels
    Sodium Channel Na channels;Na+ channels Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na +) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential. www.MedChemExpress.com 1 Sodium Channel Inhibitors & Modulators (+)-Kavain (-)-Sparteine sulfate pentahydrate Cat. No.: HY-B1671 ((-)-Lupinidine (sulfate pentahydrate)) Cat. No.: HY-B1304 Bioactivity: (+)-Kavain, a main kavalactone extracted from Piper Bioactivity: (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine sulfate methysticum, has anticonvulsive properties, attenuating pentahydrate) is a class 1a antiarrhythmic agent and a sodium vascular smooth muscle contraction through interactions with channel blocker. It is an alkaloid, can chelate the bivalents voltage-dependent Na + and Ca 2+ channels [1]. (+)-Kav… calcium and magnesium. Purity: 99.98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg 50 mg A-803467 Ajmaline Cat. No.: HY-11079 (Cardiorythmine; (+)-Ajmaline) Cat. No.: HY-B1167 Bioactivity: A 803467 is a selective Nav1.8 sodium channel blocker with an Bioactivity: Ajmaline is an alkaloid that is class Ia antiarrhythmic agent.
    [Show full text]
  • WO 2013/043925 Al FIG. 14
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/043925 Al 28 March 2013 (28.03.2013) WIPOIPCT (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 31/4196 (2006.01) A61K 45/06 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 31/495 (2006.01) A61P 3/10 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US2012/056419 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 20 September 2012 (20.09.2012) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available)·. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/537,411 21 September 2011 (21.09.2011) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: GIUEAD SCIENCES, INC. [US/US]; 333 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Lakeside Drive, Foster City, California 94404 (US).
    [Show full text]
  • Sodium Channel Na Channels; Na+ Channels
    Sodium Channel Na channels; Na+ channels Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential. www.MedChemExpress.com 1 Sodium Channel Inhibitors, Agonists, Antagonists, Activators & Modulators (+)-Kavain (-)-Sparteine sulfate pentahydrate Cat. No.: HY-B1671 ((-)-Lupinidine sulfate pentahydrate) Cat. No.: HY-B1304 (+)-Kavain, a main kavalactone extracted from Piper (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine methysticum, has anticonvulsive properties, sulfate pentahydrate) is a class 1a antiarrhythmic attenuating vascular smooth muscle contraction agent and a sodium channel blocker. It is an through interactions with voltage-dependent Na+ alkaloid, can chelate the bivalents calcium and and Ca2+ channels. magnesium. Purity: 99.98% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 10 mM × 1 mL, 50 mg (Rac)-AMG8379 20(S)-Ginsenoside Rg3 ((Rac)-AMG8380) Cat. No.: HY-108425B (20(S)-Propanaxadiol; S-ginsenoside Rg3) Cat.
    [Show full text]